Chimeric Therapeutics (ASX:CHM), an Australian cell therapy company, has ceased enrolment and dosing in its Phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results